Elevation of ADP-ribosylation as an indicator of mononuclear leucocyte responsiveness in breast cancer patients treated with tamoxifen.
82 women who had had surgery for removal of breast cancer were randomised during the primary care period before initiation of any chemotherapy or radiotherapy into two groups: no drug treatment (n = 40) and 20 mg tamoxifen per day for 2 years (n = 42). Mononuclear leucocyte (MNL) fractions from blood samples were collected during the first 368 days of the study and ADP-ribosylation was quantified. Tamoxifen treatment resulted in a dose-duration increase in ADP-ribosylation. This was true even after adjustment for covariates such as age, smoking habits, oestrogen use, menstruation and tumour size. These data suggest that part of the antitumour effects of tamoxifen treatment in vivo relates to an enhanced immune cell responsiveness, as indicated by the increased MNL ADP-ribosylation.
Pero
R W
RW
Department of Molecular Ecogenetics, University of Lund, Wallenberg Laboratory, Sweden.
Olsson
H
H
Killander
F
F
Troll
W
W
D000244:Adenosine Diphosphate / Q000378:metabolism*; D000246:Adenosine Diphosphate Ribose / Q000378:metabolism; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000201:enzymology*; D008875:Middle Aged; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism*; D012907:Smoking / Q000378:metabolism; D013629:Tamoxifen / Q000627:therapeutic use*; D013997:Time Factors
D013629:Tamoxifen; D000246:Adenosine Diphosphate Ribose; D000244:Adenosine Diphosphate; D011065:Poly(ADP-ribose) Polymerases